Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's AZD-6234?
AZD-6234 is a synthetic peptide commercialized by AstraZeneca, with a leading Phase I program in Obesity. According to Globaldata, it...
Data Insights
AZD-6234 by AstraZeneca for Obesity: Likelihood of Approval
AZD-6234 is under clinical development by AstraZeneca and currently in Phase I for Obesity. According to GlobalData, Phase I drugs...